• Dry Cracked Skin
  • Impetigo
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Surgery
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Inflamed Skin

Alefacept response lingers in psoriatic patients

Article

New Orleans - Psoriatic patients achieving >75 percentreduction in PASI score with one course of alefacept (Amevive) followedby treatment-free follow-up maintained >50 percent reduction for at leasteight months.

Related Videos
Related Content
Review Finds Topical Erythromycin, Azithromycin, and Metronidazole Most Common Treatments for Pediatric Rosacea

Review Finds Topical Erythromycin, Azithromycin, and Metronidazole Most Common Treatments for Pediatric Rosacea

Article
The Cutaneous Connection: Combatting Treatment Skepticism in Advanced Pediatric Atopic Dermatitis

The Cutaneous Connection: Combatting Treatment Skepticism in Advanced Pediatric Atopic Dermatitis

Podcast
Camp Wonder: Supporting Children With Life-Threatening Skin Diseases

Camp Wonder: Supporting Children With Life-Threatening Skin Diseases

Article
The Cutaneous Connection

The Cutaneous Connection: Episode 28- The Path to Understanding Pediatric Melanoma

Podcast
Given Prevalence, Study Underscores Need for Education Surrounding Pediatric Dermatoses in Patients With Skin of Color

Given Prevalence, Study Underscores Need for Education Surrounding Pediatric Dermatoses in Patients With Skin of Color

Article
FDA Approves Roflumilast Cream 0.3% In Children 6 to 11 Years With PsO

FDA Approves Roflumilast Cream 0.3% In Children 6 to 11 Years With PsO

Article
© 2023 MJH Life Sciences

All rights reserved.